Work

The Emergence of Escape Mutations in COVID-19 Following Anti-Spike Monoclonal Antibody Treatment: How Do We Tackle It?

Year: 2025

Type: article

Abstract: Treatment-emergent resistance to anti-Spike monoclonal antibody (mAb) was a largely unexpected and dramatic finding along the COVID-19 pandemic. Emergence of resistant strains was particularly common in immunocompromised patients, who often harbored very high SARS-CoV-2 loads when treated with mAb monotherapies. Concerns were raised regarding the risk for some of those resistant variants to propagate in communities. In this review, we will summarize the experience thus far and suggest recommendations to prevent and manage mAb treatment-emergent resistance such as comboing and reliance over polyclonal immunoglobulins.

Source: Infection and Drug Resistance

DOI: 10.2147/idr.s540928

Authors: Daniele Focosi, Massimo Franchini, Fabrizio Maggi, Arturo Casadevall

Institutions: University of Pisa, Azienda Ospedaliera Universitaria Pisana, Azienda Ospedaliera Carlo Poma, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Johns Hopkins University

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,836